Acute Myeloid Leukemia | Tumor

CURE’s acute myeloid leukemia page features the latest cancer news and updates on acute myeloid leukemia. Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in acute myeloid leukemia.

FDA Approves Komzifti for NPM1-Mutant Acute Myeloid Leukemia

November 13th 2025, 4:00pm

Article

The FDA approved Komzifti in relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.

FDA Grants Orphan Drug Designation to M2T-CD33 in AML

November 5th 2025, 4:00pm

Article

The U.S. FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.

Covering Every FDA Oncology Approval From October 2025

November 3rd 2025, 8:00pm

Article

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

Painting Passion During AML Recovery Sparked Lifelong Creative Joy

July 16th 2025, 9:00pm

Article

A watercolor set gifted during my bone marrow transplant for acute myeloid leukemia became my outlet for wonder, creativity, and lasting joy in recovery and beyond.

Healing Through Advocacy and Self-Discovery After AML Diagnosis

July 5th 2025, 2:00pm

Article

Zac Mirecki reflects on six years of survivorship, sharing how his AML journey taught him to priori-tize self-care, seek connection, and support others through advocacy.

Finding Meaning After an Acute Myeloid Leukemia Diagnosis

May 20th 2025, 9:00pm

Article

I found purpose after my AML diagnosis by reflecting on loss, embracing gratitude and using my experience to help others through their own cancer journeys.

SENTI-202 Shows Positive Preliminary Data in Acute Myeloid Leukemia

April 30th 2025, 1:00pm

Article

A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.

Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML

April 13th 2025, 6:00pm

Article

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

FDA Grants Positive Review for AML Drug Trial, First Dosing in 2025

April 8th 2025, 9:00pm

Article

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

SLS009 May Improve Survival in R/R AML

April 8th 2025, 3:00pm

Article

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.